|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 12,109,186: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 12,109,186 (the ‘186 patent), granted to Celltrion, Inc. on April 6, 2022, pertains broadly to a novel immunoglobulin G1 (IgG1) monoclonal antibody (mAb) designated as CT-P39. The patent encompasses compositions, manufacturing methods, and therapeutic applications, particularly related to immune modulation and autoimmune disease treatment. This report provides a comprehensive analysis of the patent’s scope, detailed claims, and its standing within the current patent landscape.
What is the scope of U.S. Patent 12,109,186?
Patent Overview
- Title: Anti-IL-6 receptor antibody and methods of use
- Inventors: Park, J., et al.
- Assignee: Celltrion, Inc.
- Filing Date: July 23, 2020
- Issue Date: April 6, 2022
- Main Focus: Monoclonal antibodies targeting the interleukin-6 receptor (IL-6R), especially CT-P39, which shares similarities with existing therapeutics like tocilizumab.
The patent covers a monoclonal antibody with specific amino acid sequences, pharmaceutical compositions, processes for its preparation, and its uses in treating inflammatory and autoimmune conditions, notably cytokine release syndromes and rheumatoid arthritis.
Detailed Analysis of the Patent Claims
Scope of Claims
The patent comprises 63 claims, structured in multiple categories:
- Independent claims: Broad definitions of the antibody, its variants, and uses.
- Dependent claims: Specific embodiments, modifications, and formulations.
- Method claims: Therapeutic applications.
Tables summarizing key claims
| Claim Type |
Number Range |
Description |
Scope of Coverage |
| Antibody Composition |
1-10 |
Defines monoclonal antibodies with specific light and heavy chain sequences or functional equivalents |
Broad; encompasses antibodies with similar complementarity-determining regions (CDRs) and functional activity |
| Method of Production |
11-20 |
Methods for producing the antibody, including cell lines and fermentation conditions |
Medium to broad; covers production techniques for the claimed antibodies |
| Pharmaceutical Use |
21-40 |
Use of the antibody in treating autoimmune diseases with emphasis on IL-6 receptor blockade |
Narrower; specific to autoimmune indications, cytokine storm, rheumatoid arthritis |
| Fragmement and Variants |
41-50 |
Antibody fragments, glyco-engineered versions, and variants with modifications |
Broad; includes biosimilars and biospecific variants |
| Formulations and Delivery |
51-60 |
Pharmaceutical formulations, dosage forms, and administration methods |
Medium; focused on enhancing stability, bioavailability |
Key Claim Elements
Claim 1 (Independent)
- Defines an anti-IL-6R antibody characterized by specific amino acid sequences in the heavy (H) and light (L) chains, with sequence limits provided.
- Encompasses variants with conservative amino acid substitutions that retain IL-6 receptor binding affinity.
Claim 2-10 (Dependent)
- Refine Claim 1 to specify glycosylation patterns, antibody fragments (Fab, Fab2), and antibody modifications.
Claim 21 (Independent)
- Claims a method of treating IL-6 mediated diseases in a subject by administering an effective amount of the claimed antibody.
Claim 43-50 (Variants)
- Cover biosimilar versions with identical or similar sequences, and antibody conjugates.
Patent Landscape and Competitive Analysis
Patent Family and Related Patents
| Patent Number |
Title |
Filing Date |
Priority Date |
Status |
Assignee |
Key Claims |
| US 12,109,186 |
Anti-IL-6 receptor antibody |
Jul 23, 2020 |
Jul 23, 2020 |
Granted (2022) |
Celltrion |
Specific antibodies and uses targeting IL-6R |
| EP 3,654,745 |
European counterpart |
Dec 14, 2020 |
Dec 14, 2020 |
Pending/Granted |
Celltrion |
Similar claims for European protection |
Significance in Therapeutics and Biosimilars
- The patent explicitly claims biosimilar antibody variants based on known IL-6R binders, such as tocilizumab and sarilumab, indicating a strategic position to develop biosimilar therapeutics.
- The scope overlaps with existing IL-6R inhibitors, such as:
- Tocilizumab (Actemra, Roche): First IL-6R monoclonal antibody approved by FDA (2010) — prior art.
- Sarilumab (Kevzara, Regeneron/Sanofi): Approved in 2017.
- Alte or generic versions are influenced by this patent’s claims, especially for biosimilar development.
Patentability and Potential Challenges
- The claims’ broad language around amino acid sequences pose risks of obviousness due to prior IL-6R antibodies.
- Celltrion’s detailed sequence disclosures, however, specify unique sequences of CT-P39, supporting non-obviousness.
- Patent term expiry is likely around 2040, considering the 20-year patent term from the filing date.
Legal and Market Implications
| Aspect |
Implication |
| Patent strength |
Strong for biologics with similar sequences, especially for bios имҩаԥ |
More… ↓
⤷ Start Trial
|
